智飞生物 (300122.SZ) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−2.3x

Market Cap

CNY 30.71B

MomentumView details →

1D Return

−7.70%

YTD Return

−29.78%

RSI (14)

48.9

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−2.3x

Market Cap

CNY 30.71B

RSI (14)

48.9

MomentumView details →

1D Return

−7.70%

YTD Return

−29.78%

ProfitabilityView details →

Gross Margin

6.58%

Net Margin

−168.87%

EBITDA Margin

−193.47%

ROE (TTM)

−95.68%

ROA (TTM)

−50.82%

Asset Turnover

0.29x

GrowthView details →

Revenue YoY

−48.46%

EPS YoY

—

FCF YoY

+680.14%

Revenue CAGR 3Y

−38.37%

EPS CAGR 3Y

—

EBITDA YoY

—

EarningsView details →

EPS (Actual)

−CNY 0.18

EPS Surprise

−999.90%

Beats (12Q)

0/12

Next Q EPS Est

−CNY 0.10

Avg Surprise (4Q)

−999.90%

Rev Surprise

−24.77%

Capital & dividendView details →

Debt/Equity

0.51x

Current Ratio

3.14x

Quick Ratio

2.46x

Div Yield

—

Div Rate

—

Div Growth 1Y

+100.00%

Financials snapshotView financials →

Revenue (TTM)

8.75B

Net Income (TTM)

−14.78B

Op. CF (TTM)

5.11B

Next earningsOct 23, 2026 →

Latest newsMore news →

Zhifei Biological's subsidiary Chongqing Chen'an Biotech officially launched its liraglutide injection (Dashuchen) into the market with a shipment ceremony on September 4, 2026.12h ago

Zhifei Biological's subsidiary Anhui Zhifei Longcom Biopharmaceutical received acceptance from China's National Medical Products Administration for its clinical trial application of a freeze-dried human rabies vaccine (ZFB-3 cells), allowing trials to proceed within 60 days if no objections are raised.3d ago

Similar companies

东阿阿胶000423.SZ 汇绿生态001267.SZ 蔚蓝锂芯002245.SZ 章源钨业002378.SZ 新希望000876.SZ 欧陆通300870.SZ Find similar companies →

Latest newsMore news →

Zhifei Biological's subsidiary Chongqing Chen'an Biotech officially launched its liraglutide injection (Dashuchen) into the market with a shipment ceremony on September 4, 2026.12h ago Zhifei Biological's subsidiary Anhui Zhifei Longcom Biopharmaceutical received acceptance from China's National Medical Products Administration for its clinical trial application of a freeze-dried human rabies vaccine (ZFB-3 cells), allowing trials to proceed within 60 days if no objections are raised.3d ago